Plain English version. The pancreatic program tests a compact set of blood derived mRNA markers and runs them through an AI assisted model to detect pancreatic ductal adenocarcinoma and tell it apart from IPMN. The AACR read is a 30 subject verification, not a pivotal. That is early, but it should answer whether a trimmed panel keeps signal quality.
What to demand in the abstract and poster. Report sensitivity, specificity, and AUC. Break out performance by stage I and II. Show IPMN subgroup results and list confounders like chronic pancreatitis or jaundice. Confirm sample handling, blinding, and site count. Then give a dated plan for a larger blinded validation with the target sample size.
Why it matters for MYNZ. A credible PDAC blood test would sit next to ColoAlert and improve platform economics if labs can run both. If the metrics are soft or poorly disclosed, treat it as a science milestone, not a commercial one.
Not financial advice. Do your own research.